


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously amended) A compound of formula (I):



wherein **A** is 5-membered heteroaryl containing a nitrogen atom and optionally containing one or two further nitrogen atoms;

**X** is O, S, S(O), S(O)<sub>2</sub> or NR<sup>14</sup>;

**m** is 0, 1, 2 or 3;

**Z** is a group selected from -NR<sup>1</sup>R<sup>2</sup>, phosphonooxy, C<sub>3-6</sub>cycloalkyl which C<sub>3-6</sub>cycloalkyl is substituted by phosphonooxy or C<sub>1-4</sub>alkyl substituted by phosphonooxy, and a 4- to 7-membered ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, which ring may be saturated, partially saturated or unsaturated wherein the ring is substituted on carbon or nitrogen by phosphonooxy or C<sub>1-4</sub>alkyl substituted by phosphonooxy, and wherein the ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C<sub>1-4</sub>alkyl groups;

**R**<sup>1</sup> is a group selected from -COR<sup>8</sup>, -CONR<sup>8</sup>R<sup>9</sup> and C<sub>1-6</sub>alkyl which C<sub>1-6</sub>alkyl is substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

**R**<sup>2</sup> is a group selected from hydrogen, -COR<sup>10</sup>, -CONR<sup>10</sup>R<sup>11</sup> and C<sub>1-6</sub>alkyl which C<sub>1-6</sub>alkyl is optionally substituted by 1, 2 or 3 halo or C<sub>1-4</sub>alkoxy groups or -S(O)<sub>p</sub>R<sup>11</sup> (where p is 0, 1 or 2) or phosphonooxy, or R<sup>2</sup> is a group selected from C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>3-6</sub>cycloalkyl and C<sub>3-6</sub>cycloalkylC<sub>1-4</sub>alkyl;

or **R**<sup>1</sup> and **R**<sup>2</sup> together with the nitrogen to which they are attached form a 4- to 7- membered ring optionally containing a further nitrogen atom which ring may be saturated, unsaturated or partially saturated wherein the ring is substituted on carbon or nitrogen by a group selected from

phosphonoxy and C<sub>1-4</sub>alkyl which C<sub>1-4</sub>alkyl is substituted by phosphonoxy or -NR<sup>8</sup>R<sup>9</sup>, and where the ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C<sub>1-4</sub>alkyl groups;

**R**<sup>3</sup> is a group selected from hydrogen, halo, cyano, nitro, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkyl, -OR<sup>12</sup>, -CHR<sup>12</sup>R<sup>13</sup>, -OC(O)R<sup>12</sup>, -C(O)R<sup>12</sup>, -NR<sup>12</sup>C(O)R<sup>13</sup>, -C(O)NR<sup>12</sup>R<sup>13</sup>, -NR<sup>12</sup>SO<sub>2</sub>R<sup>13</sup> and -NR<sup>12</sup>R<sup>13</sup>;

**R**<sup>4</sup> is hydrogen or a group selected from C<sub>1-4</sub>alkyl, heteroaryl, heteroarylC<sub>1-4</sub>alkyl, aryl and arylC<sub>1-4</sub>alkyl which group is optionally substituted by 1, 2 or 3 substituents selected from halo, methyl, ethyl, cyclopropyl and ethynyl;

**R**<sup>5</sup> is selected from hydrogen, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>3-6</sub>cycloalkyl and C<sub>3-6</sub>cycloalkylC<sub>1-4</sub>alkyl;

**R**<sup>6</sup> and **R**<sup>7</sup> are independently selected from hydrogen, halo, C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, hydroxy and C<sub>1-4</sub>alkoxy;


**R**<sup>8</sup> is C<sub>1-4</sub>alkyl substituted by phosphonoxy and optionally further substituted by 1 or 2 halo or methoxy groups;

**R**<sup>9</sup> is selected from hydrogen and C<sub>1-4</sub>alkyl;


**R**<sup>10</sup> is selected from hydrogen and C<sub>1-4</sub>alkyl (optionally substituted by halo, C<sub>1-4</sub>alkoxy, S(O)<sub>q</sub> (where q is 0, 1 or 2) or phosphonoxy);

**R**<sup>11</sup>, **R**<sup>12</sup>, **R**<sup>13</sup> and **R**<sup>14</sup> are independently selected from hydrogen, C<sub>1-4</sub>alkyl and heterocycl; or a pharmaceutically acceptable salt thereof.


2. (original) A compound according to claim 1 wherein A is a group of formula (a), (b), (c), (d) or (e):




(a)




(b)



(c)



(d)



(e)

where \* is the point of attachment to the X group of formula (I) and \*\* is the point of attachment to the (CR<sup>6</sup>R<sup>7</sup>) group of formula (I); or a pharmaceutically acceptable salt thereof.

3. (original) A compound according to claim 2 wherein A is a group of formula (a) as defined in claim 2; or a pharmaceutically acceptable salt thereof.

4. (Previously amended) A compound according to claim 1 wherein X is NH; or a pharmaceutically acceptable salt thereof.

5. (Previously amended) A compound according to claim 1 wherein Z is -NR<sup>1</sup>R<sup>2</sup> or a 5- to 6-membered saturated ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, wherein the ring is substituted on carbon or nitrogen by phosphonoxy or C<sub>1-4</sub>alkyl substituted by phosphonoxy; or a pharmaceutically acceptable salt thereof.

6. (Previously amended) A compound according to claim 1 wherein R<sup>1</sup> is C<sub>1-5</sub>alkyl substituted by phosphonoxy and R<sup>2</sup> is a group selected from hydrogen and C<sub>1-6</sub>alkyl which C<sub>1-6</sub>alkyl is optionally substituted by 1, 2 or 3 halo or C<sub>1-4</sub>alkoxy groups, or R<sup>2</sup> is a group selected from C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>3-6</sub>cycloalkyl and C<sub>3-6</sub>cycloalkylC<sub>1-4</sub>alkyl; or a pharmaceutically acceptable salt thereof.

7. (Previously amended) A compound according to claim 1 wherein R<sup>1</sup> is 2-phosphonooxyethyl; or a pharmaceutically acceptable salt thereof.

8. (Previously amended) A compound according to claim 1 where Z is –NR<sup>1</sup>R<sup>2</sup> and R<sup>1</sup> and R<sup>2</sup> together with the nitrogen to which they are attached form a piperidine, pyrrolidine or piperazine ring which is substituted by a group selected from phosphonooxy, phosphonoxymethyl, 2-phosphonooxyethyl, N-ethyl-N-(2-phosphonooxyethyl)aminomethyl and N-(2-phosphonooxyethyl)aminomethyl and where the ring is optionally further substituted by 1 or 2 methyl; or a pharmaceutically acceptable salt thereof.

9. (original) A compound according to claim 8 wherein R<sup>1</sup> and R<sup>2</sup> together with the nitrogen to which they are attached form 2-(phosphonoxymethyl)pyrrolidinyl; or a pharmaceutically acceptable salt thereof.

10. (Previously amended) A compound according to claim 1 wherein R<sup>4</sup> is 3-fluorophenyl, 3,5-difluorophenyl or 2,3-difluorophenyl; or a pharmaceutically acceptable salt thereof.

11. (Previously amended) A compound according to claim 1 wherein R<sup>3</sup> is C<sub>1-4</sub>alkoxy, halo or hydrogen; or a pharmaceutically acceptable salt thereof.

12. (original) A compound selected from:

{1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl}methyl dihydrogen phosphate;  
2-[[3-({4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate;  
{(2S)-1-[3-({4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;  
{(2R)-1-[3-({4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;  
{(2S)-1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;  
2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](propyl)amino]ethyl dihydrogen phosphate;

2-[[3-(4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl](isobutyl)amino]ethyl dihydrogen phosphate;

2-[[3-(4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl](isobutyl)amino]ethyl dihydrogen phosphate;

2-[[3-(4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl](propyl)amino]ethyl dihydrogen phosphate;

2-[[3-(4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl](isobutyl)amino]ethyl dihydrogen phosphate;

2-[(2,2-dimethylpropyl)[3-(4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl]amino]ethyl dihydrogen phosphate;

1-[3-(4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl]piperidin-3-yl dihydrogen phosphate;

{(2*R*)-1-[3-(4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;

2-[[3-(4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl](prop-2-yn-1-yl)amino]ethyl dihydrogen phosphate;

2-[[3-(4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl](isopropyl)amino]ethyl dihydrogen phosphate;

2-[[3-(4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl](prop-2-yn-1-yl)amino]ethyl dihydrogen phosphate;

2-[[3-(4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl](2-methoxyethyl)amino]ethyl dihydrogen phosphate;

2-{{3-(4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl}amino}ethyl dihydrogen phosphate;

2-{{(cyclobutylmethyl)[3-(4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl}amino}ethyl dihydrogen phosphate;

2-[[3-(4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl](3,3,3-trifluoropropyl)amino]ethyl dihydrogen phosphate;

2-{{allyl}[3-(4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl}amino]ethyl dihydrogen phosphate;

2-{{cyclobutyl}[3-(4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl}amino]ethyl dihydrogen phosphate;

2-{{cyclopentyl}[3-(4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl]oxy)propyl}amino]ethyl dihydrogen phosphate;

2-{cyclopropyl[3-(4-[5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy]propyl}amino}ethyl dihydrogen phosphate;

2-{(cyclopropylmethyl)[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy]propyl}amino}ethyl dihydrogen phosphate;

2-{cyclobutyl[3-(4-[5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy]propyl}amino}ethyl dihydrogen phosphate;

2-{4-[(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)methyl]piperidin-1-yl}ethyl dihydrogen phosphate;

2-[[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl](ethyl)amino}ethyl dihydrogen phosphate;

2-[[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl](isopropyl)amino}ethyl dihydrogen phosphate;

3-{[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy]propyl}amino}3-methylbutyl dihydrogen phosphate;

2-{(2*S*)-1-[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl]pyrrolidin-2-yl}ethyl dihydrogen phosphate;

{(2*R*)-1-[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;

2-[[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl](propyl)amino}ethyl dihydrogen phosphate;

2-[[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl](butyl)amino}ethyl dihydrogen phosphate;

2-{cyclopentyl[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl}amino}ethyl dihydrogen phosphate;

{(2*S*)-1-[3-(4-[5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;

{(2*S*)-1-[3-(4-[5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;

2-{cyclopentyl[3-(4-[5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl}amino}ethyl dihydrogen phosphate;

2-[[3-(4-[5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy]propyl](ethyl)amino}ethyl dihydrogen phosphate;

2-[[3-(4-[5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy]propyl]amino}2-methylpropyl dihydrogen phosphate;

2-[[3-(*{*4-[*{*5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](propyl)amino]ethyl dihydrogen phosphate;

{(2*R*)-1-[3-(*{*4-[*{*5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;

3-[[3-(*{*4-[*{*5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]propyl dihydrogen phosphate

2-[[3-(*{*4-[*{*5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl](2-methoxyethyl)amino]ethyl dihydrogen phosphate

2-[[4-(*{*4-[*{*5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)butyl](propyl)amino]ethyl dihydrogen phosphate;

2-[[4-(*{*4-[*{*5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)butyl](ethyl)amino]ethyl dihydrogen phosphate;

{(2*R*)-1-[4-(*{*4-[*{*5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)butyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;

2-[[4-(*{*4-[*{*5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)butyl](methyl)amino]ethyl dihydrogen phosphate;

{(2*S*)-1-[4-(*{*4-[*{*5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)butyl]pyrrolidin-2-yl}methyl dihydrogen phosphate; and

2-{ethyl}[3-(*{*6-fluoro-4-[*{*5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino]ethyl dihydrogen phosphate;

or a pharmaceutically acceptable salt thereof.

13. (Previously amended) A pharmaceutical composition comprising a compound according to claim 1 in association with a pharmaceutically acceptable diluent or carrier.


14.-17. (cancelled)

18. (Previously amended) A method of treating a human suffering from a disease in which the inhibition of one or more Aurora kinases is beneficial, comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

19. (Previously amended) A method of treating a human suffering from colorectal, breast, lung, prostate, pancreatic or bladder and renal cancer or leukemias or lymphomas, comprising the

steps of administering to a person in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

20. (Previously amended) A process for the preparation of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (II) into a compound of formula (I) by phosphorylation of an appropriate hydroxy group:



where A, X, m, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>9</sup> are as defined for formula (I); and Z' is a group selected from –NR<sup>1</sup>R<sup>2</sup>, hydroxy, C<sub>3-6</sub>cycloalkyl which C<sub>3-6</sub>cycloalkyl is substituted by hydroxy or C<sub>1-4</sub>alkyl substituted by hydroxy, and a 4- to 7-membered ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, which ring may be saturated, unsaturated or partially saturated wherein the ring is substituted on carbon or nitrogen by hydroxy or C<sub>1-4</sub>alkyl substituted by hydroxy and wherein the ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C<sub>1-4</sub>alkyl groups; R<sup>1</sup> is a group selected from –COR<sup>8</sup>, –CONR<sup>8</sup>R<sup>9</sup> and C<sub>1-6</sub>alkyl which C<sub>1-6</sub>alkyl is substituted by hydroxy and optionally further substituted by 1 or 2 halo or methoxy groups; R<sup>2</sup> is a group selected from hydrogen, –COR<sup>10</sup>, –CONR<sup>10</sup>R<sup>11</sup> and C<sub>1-6</sub>alkyl which C<sub>1-6</sub>alkyl is optionally substituted by 1, 2 or 3 halo or C<sub>1-4</sub>alkoxy groups or –S(O)<sub>p</sub>R<sup>11</sup> (where p is 0, 1 or 2) or hydroxy, or R<sup>2</sup> is a group selected from C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>3-6</sub>cycloalkyl and C<sub>3-6</sub>cycloalkylC<sub>1-4</sub>alkyl; or R<sup>1</sup> and R<sup>2</sup> together with the nitrogen to which they are attached form a 4- to 7- membered ring optionally containing a further nitrogen atom which may be saturated, unsaturated or partially saturated wherein the ring is substituted on carbon or nitrogen by a group selected from hydroxy and C<sub>1-4</sub>alkyl which C<sub>1-4</sub>alkyl is substituted by hydroxy or –NR<sup>8</sup>R<sup>9</sup> and where the ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C<sub>1-4</sub>alkyl groups; and

where  $\mathbf{R}^8$  is  $\text{C}_{1-4}\text{alkyl}$  substituted by hydroxy and optionally further substituted by 1 or 2 halo or methoxy groups;


and thereafter if necessary:

- i) converting a compound of formula (I) into another compound of formula (I); and/or
- ii) removing any protecting groups; and/or
- iii) forming a pharmaceutically acceptable salt thereof.


21. (Previously Added) The method according to claim 18 wherein Aurora kinase is Aurora-A kinase or Aurora-B kinase.

22. (Previously Added) A compound according to claim 1, wherein:


**A** is a group of formula (a), (b), (c), (d) or (e):




(a)




(b)



(c)



(d)



(e)

where \* is the point of attachment to the  $\mathbf{X}$  group of formula (I) and \*\* is the point of attachment to the  $(\text{CR}^6\text{R}^7)$  group of formula (I);

$\mathbf{X}$  is  $\text{NH}$ ;

$\mathbf{m}$  is 0, 1, 2 or 3;

$\mathbf{Z}$  is  $-\text{NR}^1\text{R}^2$  or a 5- to 6-membered saturated ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, which ring is substituted on carbon or nitrogen by phosphonoxy or  $\text{C}_{1-4}\text{alkyl}$  substituted by phosphonoxy;

$\mathbf{R}^1$  is  $\text{C}_{1-5}\text{alkyl}$  substituted by phosphonoxy;

**R<sup>2</sup>** is selected from hydrogen and C<sub>1-6</sub>alkyl which C<sub>1-6</sub>alkyl is optionally substituted by 1, 2 or 3 halo or C<sub>1-4</sub>alkoxy groups or **R<sup>2</sup>** is selected from C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>3-6</sub>cycloalkyl and C<sub>3-6</sub>cycloalkylC<sub>1-4</sub>alkyl;

or **R<sup>1</sup>** and **R<sup>2</sup>** together with the nitrogen to which they are attached form a saturated 5- to 6-membered ring optionally containing a further nitrogen atom wherein the ring is substituted on carbon or nitrogen by a group selected from phosphonooxy and C<sub>1-4</sub>alkyl which C<sub>1-4</sub>alkyl is substituted by phosphonooxy or –NR<sup>8</sup>R<sup>9</sup>, and where the ring is optionally further substituted on carbon or nitrogen by 1 or 2 C<sub>1-4</sub>alkyl groups;

**R<sup>3</sup>** is C<sub>1-4</sub>alkoxy, halo or hydrogen;

**R<sup>4</sup>** is phenyl optionally substituted by 1 or 2 of fluoro or chloro;


**R<sup>5</sup>** is hydrogen or methyl; and

**R<sup>6</sup>** and **R<sup>7</sup>** are independently hydrogen, fluoro, chloro or methyl;

or a pharmaceutically acceptable salt thereof.

23. (Previously Added) A compound according to claim 1, wherein:

**A** is a group of formula (a):



where \* is the point of attachment to the X group of formula (I) and \*\* is the point of attachment to the (CR<sup>6</sup>R<sup>7</sup>) group of formula (I);

**X** is NH;

**m** is 1, 2 or 3;

**Z** is –NR<sup>1</sup>R<sup>2</sup>;

**R<sup>1</sup>** is C<sub>1-5</sub>alkyl substituted by phosphonooxy;

**R<sup>2</sup>** is selected from hydrogen and C<sub>1-6</sub>alkyl which C<sub>1-6</sub>alkyl is optionally substituted by 1, 2 or 3 halo or C<sub>1-4</sub>alkoxy groups, or **R<sup>2</sup>** is selected from C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>3-6</sub>cycloalkyl and C<sub>3-6</sub>cycloalkylC<sub>1-4</sub>alkyl;

**R<sup>3</sup>** is C<sub>1-4</sub>alkoxy, halo or hydrogen;

**R<sup>4</sup>** is phenyl optionally substituted by 1 or 2 of fluoro or chloro;


**R<sup>5</sup>** is hydrogen; and

**R<sup>6</sup>** and **R<sup>7</sup>** are each hydrogen;

or a pharmaceutically acceptable salt thereof.

24. (Previously Added) A compound according to claim 1 wherein:

**A** is a group of formula (a):



(a)

where \* is the point of attachment to the X group of formula (I) and \*\* is the point of attachment to the (CR<sup>6</sup>R<sup>7</sup>) group of formula (I);

**X** is NH;

**m** is 1, 2 or 3;

**Z** is -NR<sup>1</sup>R<sup>2</sup>;

**R**<sup>1</sup> is C<sub>1-5</sub>alkyl substituted by phosphonoxy;

**R**<sup>2</sup> is selected from hydrogen and C<sub>1-6</sub>alkyl which C<sub>1-6</sub>alkyl is optionally substituted by 1, 2 or 3 halo or C<sub>1-4</sub>alkoxy groups, or **R**<sup>2</sup> is selected from C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>3-6</sub>cycloalkyl and C<sub>3-6</sub>cycloalkylC<sub>1-4</sub>alkyl;

**R**<sup>3</sup> is hydrogen;

**R**<sup>4</sup> is phenyl optionally substituted by 1 or 2 of fluoro or chloro;

**R**<sup>5</sup> is hydrogen; and

**R**<sup>6</sup> and **R**<sup>7</sup> are each hydrogen;

or a pharmaceutically acceptable salt thereof.

25. (Previously Added) A pharmaceutical composition comprising a compound according to claim 12 in association with a pharmaceutically acceptable diluent or carrier.

26. (New) A compound which is *N*-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1*H*-pyrazol-5-yl}acetamide, or a pharmaceutically acceptable salt thereof.